Special Issue "Human Leukocyte Antigen (HLA) and Vaccines"
Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 4141
Interests: human leukocyte antigen; vaccines; gulf war illness; dementia; healthy brain aging; magnetoencephalography; neural mechanisms of cognitive processes; neurophysiology of motor control and cognition; functional MRI of motor and cognitive processes
Interests: cell biology and biochemistry; vaccines; gulf war illness; neurodegenerative diseases
Interests: Aging; Dementia; Human Leukocyte Antigen; PTSD; resilience
The success of vaccines in preventing illness depends on our ability to make antibodies against the pathogen components contained in the vaccines; if antibodies cannot be made, the vaccine will not be effective. In this case, vaccine antigens persist with the possibility of causing cell damage either directly or via molecular mimicry and autoimmunity. Now, the mounting of antibodies against specific antigens critically depends on the individual's Human Leukocyte Antigen (HLA) Class 2 genetic makeup, which consists of more than six alleles (two for each of the DRB1, DQB1, and DPB1 genes, plus the occasional DRB3, DRB4, and DRB5 allele). This Special Issue will focus on this matter, which is of major medical and public health importance but hardly covered elsewhere.
Prof. Apostolos P. Georgopoulos
Dr. Effie-Photini Tsilibary
Dr. Lisa M. James
Dr. Spyros Charonis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- persistent antigens
- human leukocyte antigen
- neural cultures